Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2000 1
2002 1
2003 1
2005 1
2006 2
2007 1
2010 3
2011 1
2012 1
2013 2
2014 4
2015 5
2016 7
2017 4
2018 5
2019 13
2020 7
2021 4
2022 5
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Foreword.
Reichardt P. Reichardt P. Future Oncol. 2019 Sep;15(26s):1-3. doi: 10.2217/fon-2019-0487. Epub 2019 Sep 10. Future Oncol. 2019. PMID: 31500457 Free article. No abstract available.
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Weiss AR, et al. Lancet Oncol. 2020 Aug;21(8):1110-1122. doi: 10.1016/S1470-2045(20)30325-9. Epub 2020 Jul 20. Lancet Oncol. 2020. PMID: 32702309 Free PMC article. Clinical Trial.
BACKGROUND: Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near complete response rate …
BACKGROUND: Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy …
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
Lee AT, Pollack SM, Huang P, Jones RL. Lee AT, et al. Curr Treat Options Oncol. 2017 Mar;18(3):19. doi: 10.1007/s11864-017-0457-1. Curr Treat Options Oncol. 2017. PMID: 28332083 Free PMC article. Review.
Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II data that guided the selection of …
Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for adva …
Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective.
Bae S, Brnabic A, Crowe P, Carey-Smith R, Andelkovic V, Singhal N, Stalley P, Yip D, Desai J. Bae S, et al. Asia Pac J Clin Oncol. 2022 Dec;18(6):605-613. doi: 10.1111/ajco.13706. Epub 2022 Jan 30. Asia Pac J Clin Oncol. 2022. PMID: 35098667
AIM: Despite lack of advances in the first-line systemic therapy, the overall survival (OS) has continued to improve in patients with advanced soft tissue sarcoma (STS) with the recent estimation of median OS at 20 months. ...
AIM: Despite lack of advances in the first-line systemic therapy, the overall survival (OS) has continued to improve in patients with adv …
Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Shamai S, Merimsky O. Shamai S, et al. Isr Med Assoc J. 2018 Oct;20(10):599-603. Isr Med Assoc J. 2018. PMID: 30324774 Free article.
Food and Drug Administration approval for use in anthracycline-resistant advanced soft tissue sarcoma (STS), especially liposarcoma and leiomyosarcoma (L-sarcomas). ...
Food and Drug Administration approval for use in anthracycline-resistant advanced soft tissue sarcoma (STS), esp …
Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R, Marrari A, Santoro A. De Sanctis R, et al. Expert Opin Pharmacother. 2016 Aug;17(11):1569-77. doi: 10.1080/14656566.2016.1204295. Epub 2016 Jul 4. Expert Opin Pharmacother. 2016. PMID: 27328277 Review.
INTRODUCTION: Trabectedin, a marine-derived DNA-binding antineoplastic agent, has been registered by the EMA and recently also by the FDA for the treatment of patients with advanced soft-tissue sarcoma (STS), a rare and heterogeneous disease. ...
INTRODUCTION: Trabectedin, a marine-derived DNA-binding antineoplastic agent, has been registered by the EMA and recently also by the FDA fo …
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival.
Garbay D, Maki RG, Blay JY, Isambert N, Piperno Neumann S, Blay C, Zanardi E, Boudou-Rouquette P, Bozec L, Duffaud F, Bertucci F, Italiano A. Garbay D, et al. Ann Oncol. 2013 Jul;24(7):1924-1930. doi: 10.1093/annonc/mdt059. Epub 2013 Mar 13. Ann Oncol. 2013. PMID: 23493135 Free article.
BACKGROUND: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients. PATIENTS AND METHODS: We retrospectively reviewed the charts of patients 75 years old diagnosed with metastatic or unresectable STS betwee …
BACKGROUND: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients …
66 results